Heart drug’s safety scrutinized

USA Today, July 25, 2008

A study that linked the heart drug Vytorin to excess cancer deaths has provoked controversy among heart specialists worried that the drug's risks may outweigh its benefits. The study, called SEAS, was designed to test whether Vytorin could prevent severe, age-related heart valve problems by reducing cholesterol. But lead investigator Terje Pedersen of Ulleval University Hospital reported that the study turned up a link to cancer. At that same session, Oxford University experts released a separate analysis comparing SEAS data with two other ongoing studies and concluded that the cancer link was not credible.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.